厌氧菌对氨苄西林-舒巴坦和阿莫西林-克拉维酸敏感性体外检测方法的评估。
Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid.
作者信息
Fuchs P C, Barry A L, Jones R N
机构信息
St. Vincent Hospital and Medical Center, Portland, Oregon 97225.
出版信息
J Clin Microbiol. 1988 Jun;26(6):1246-7. doi: 10.1128/jcm.26.6.1246-1247.1988.
Abstract
A total of 97 anaerobic bacteria were tested for susceptibility to ampicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid by broth microdilution and disk elution methods, the results of which were compared with those of the reference agar dilution method. With the broth microdilution method, approximately 95% of MICs were within 1 dilution of those of the reference agar method, with a definite (0.6 to 0.7 dilution) trend toward lower MICs. The disk elution test performed satisfactorily, but additional anaerobic isolates resistant to ampicillin-sulbactam and/or amoxicillin-clavulanic acid (currently rare) are needed to assure the predictability of resistance by the disk elution test.
摘要
通过肉汤微量稀释法和纸片洗脱法对总共97株厌氧菌进行了氨苄西林、氨苄西林-舒巴坦和阿莫西林-克拉维酸的药敏试验，并将结果与参考琼脂稀释法的结果进行比较。采用肉汤微量稀释法时，约95%的最低抑菌浓度（MIC）与参考琼脂法的结果相差在1个稀释度以内，且有明确（0.6至0.7个稀释度）的趋势显示MIC较低。纸片洗脱试验表现良好，但需要更多对氨苄西林-舒巴坦和/或阿莫西林-克拉维酸耐药的厌氧分离株（目前较为罕见），以确保纸片洗脱试验对耐药性预测的准确性。
相似文献
1
Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid.厌氧菌对氨苄西林-舒巴坦和阿莫西林-克拉维酸敏感性体外检测方法的评估。
J Clin Microbiol. 1988 Jun;26(6):1246-7. doi: 10.1128/jcm.26.6.1246-1247.1988.
2
[Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].[琼脂扩散法预测大肠埃希菌对氨苄西林-舒巴坦和阿莫西林-克拉维酸敏感性的误差]
Enferm Infecc Microbiol Clin. 1996 May;14(5):308-10.
3
Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.氨苄西林-舒巴坦组合的最佳稀释药敏试验条件、MIC解释建议及质量控制指南。
J Clin Microbiol. 1987 Oct;25(10):1920-5. doi: 10.1128/jcm.25.10.1920-1925.1987.
4
Comparison of ampicillin/sulbactam and amoxicillin/clavulanic acid for detection of borderline oxacillin-resistant Staphylococcus aureus.
Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):47-51. doi: 10.1007/BF01971271.
5
Broth-disk elution tests to predict the susceptibility of anaerobic bacteria to the ampicillin-sulbactam combination.肉汤纸片洗脱试验预测厌氧菌对氨苄西林-舒巴坦联合制剂的敏感性。
Diagn Microbiol Infect Dis. 1990 Jul-Aug;13(4):353-5. doi: 10.1016/0732-8893(90)90031-p.
6
Possible prevention of in vitro selection of resistant Streptococcus pneumoniae by beta-lactamase inhibitors.β-内酰胺酶抑制剂对肺炎链球菌体外耐药性选择的可能预防作用。
Eur J Clin Microbiol Infect Dis. 1994 Dec;13(12):1058-62. doi: 10.1007/BF02111828.
7
Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.对具有不同β-内酰胺耐药表型的大肠埃希菌分离株进行氨苄西林-舒巴坦和阿莫西林-克拉维酸药敏试验。
Antimicrob Agents Chemother. 1999 Apr;43(4):862-7. doi: 10.1128/AAC.43.4.862.
8
Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.β-内酰胺酶抑制剂YTR 830、克拉维酸钠和舒巴坦与阿莫西林或氨苄西林联合使用的比较活性。
Antimicrob Agents Chemother. 1984 Oct;26(4):580-2. doi: 10.1128/AAC.26.4.580.
9
In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae.
Diagn Microbiol Infect Dis. 1993 Aug-Sep;17(2):171-5. doi: 10.1016/0732-8893(93)90030-b.
10
Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.阿莫西林-克拉维酸与氨苄西林-舒巴坦对脆弱拟杆菌-大肠埃希菌混合感染的实验性疗效比较。
Antimicrob Agents Chemother. 1988 Dec;32(12):1830-3. doi: 10.1128/AAC.32.12.1830.
引用本文的文献
1
Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.394株脆弱拟杆菌、非脆弱拟杆菌属拟杆菌种及梭杆菌属细菌对新型抗菌药物的敏感性
Antimicrob Agents Chemother. 1991 Jun;35(6):1214-8. doi: 10.1128/AAC.35.6.1214.
2
Current antimicrobial therapy of anaerobic infections.当前厌氧菌感染的抗菌治疗
Eur J Clin Microbiol Infect Dis. 1992 Nov;11(11):999-1011. doi: 10.1007/BF01967790.
本文引用的文献
1
CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.CP - 45,899与青霉素或氨苄青霉素联合用于对抗耐青霉素的葡萄球菌、流感嗜血杆菌和拟杆菌。
Antimicrob Agents Chemother. 1980 Apr;17(4):615-22. doi: 10.1128/AAC.17.4.615.
2
Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.β-内酰胺酶抑制剂YTR 830、克拉维酸和舒巴坦与β-内酰胺联合应用对产β-内酰胺酶厌氧菌的比较活性
Antimicrob Agents Chemother. 1986 Nov;30(5):789-91. doi: 10.1128/AAC.30.5.789.
3
In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.舒巴坦联合氨苄西林对厌氧菌的体外疗效
Antimicrob Agents Chemother. 1985 May;27(5):876-8. doi: 10.1128/AAC.27.5.876.
4
Comparative inhibition beta-lactamases by novel beta-lactam compounds.新型β-内酰胺化合物对β-内酰胺酶的抑制作用比较
Antimicrob Agents Chemother. 1979 Feb;15(2):171-6. doi: 10.1128/AAC.15.2.171.
5
Clavulanic acid, a novel inhibitor of beta-lactamases.克拉维酸，一种新型β-内酰胺酶抑制剂。
Antimicrob Agents Chemother. 1978 Nov;14(5):650-5. doi: 10.1128/AAC.14.5.650.
6
CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.CP-45899，一种可扩展β-内酰胺类抗菌谱的β-内酰胺酶抑制剂：初步细菌学特征
Antimicrob Agents Chemother. 1978 Sep;14(3):414-9. doi: 10.1128/AAC.14.3.414.
7
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.棒酸与青霉素、阿莫西林和羧苄西林联合应用的体外研究。
Antimicrob Agents Chemother. 1978 Mar;13(3):389-93. doi: 10.1128/AAC.13.3.389.
Zotero 插件